Polycystic Kidney Disease Drugs Market Outlook:
Polycystic Kidney Disease Drugs Market size was over USD 571.38 million in 2025 and is projected to reach USD 1.1 billion by 2035, witnessing around 6.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of polycystic kidney disease drugs is evaluated at USD 606.35 million.
The growth of the market can be attributed to the worldwide increasing incidence of chronic kidney diseases, resulting in death and serious medical issues. In accordance with the Centers for Disease Control and Prevention, a total of 37 million Americans are estimated to have chronic kidney disease, which is 15% of the region's population. Further, the growing prevalence of hypertension, and surging research and development activities for the development of chronic kidney disease drugs are some further factors that are anticipated to massively drive the market’s growth further over the projected time frame.
In addition to these, factors that are believed to fuel the market growth of polycystic kidney disease drugs include the rise in PKD drug trials, followed by the growth in the approval of novel drugs by the government, along with the development of a wide range of medications by key players are anticipated to expand the global polycystic kidney disease drugs market size during the forecast period. For instance, Reata Pharmaceuticals, Inc. announced positive phase II results for bardoxolone methyl in chronic renal disease caused by Alport syndrome and autosomal dominant polycystic kidney disease in July 2018. Additionally, growing awareness about kidney diseases among people is also predicted to present the potential for market expansion over the projected period.
